person · Reporting owner
Dockendorff Charles J
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director | May 09, 2024 | May 13, 2024 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2025 | July 25, 2025 |
| Keysight Technologies, Inc.KEYS · Entity 3021 | Director | March 20, 2026 | March 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date May 09, 2024 · Filed May 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,901 |
Reported balance
After 2024-05-09 transaction · row 1
1 source rowRow 1 · 2024-05-09 · Grant · Acquired 2,901 · Balance 2,901 F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse's Trust | 42,622 |
Reported balance
Holding disclosure · report date 2024-05-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 42,622 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 17,380 |
Reported balance
Holding disclosure · report date 2024-05-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,380 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
HAEMONETICS CORP
Report date July 24, 2025 · Filed July 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,126 |
Reported balance
After 2025-07-24 transaction · row 1
1 source rowRow 1 · 2025-07-24 · Grant · Acquired 2,693 · Balance 7,126 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| Common StockSEC Table I · non-derivative | IndirectSpouse?s Revocable Trust | 17,915 |
Reported balance
Holding disclosure · report date 2025-07-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,915 |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Keysight Technologies, Inc.
Report date March 20, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,213.418 |
Reported balance
After 2026-03-20 transaction · row 1
1 source rowRow 1 · 2026-03-20 · Grant · Acquired 870 · Balance 55,213.418 F1: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 6,626 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 15,370 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.24 · Expires 2027-05-15 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 5,396 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F4: For Footnote (4), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: For Footnote (4), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | Not disclosed Strike: $64.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 10 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,536 | Not disclosed Strike: $76.32 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 9 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,536 shares Expires 2034-03-07 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,210 | Not disclosed Strike: $78.49 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 8 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,210 shares Expires 2033-03-09 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,293 | Not disclosed Strike: $70.28 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 7 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,055 | Not disclosed Strike: $71.03 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 6 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 7,322 | Not disclosed Strike: $47.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 5 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,523 | Not disclosed Strike: $46.81 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 4 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,396 | Not disclosed Strike: $43.24 | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · derivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,396 shares Expires 2027-05-15 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 15,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3 · price: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:04 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 6,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000061 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2 · price: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 10:07 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001400563-26-000002 · wk-form4_1774346871.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,213.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:15 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 3,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000017 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,626 F1 · shares: Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019594 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,126 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 14:20 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-25-000033 · wk-form4_1742912437.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:14 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | $0.00 Strike: $64.36 | $0.00 |
DisclosureSEC source: 0001127602-25-007230 · form4.xml · derivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,535 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F3 · derivative.exercise_date: Options become exercisable on the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:14 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007230 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,436 F1 · shares: Represents restricted stock units which vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021037 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,433 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 2,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005966 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,901 F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 07, 2024 Filed May 8, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,946 | $72.70 | $286,874.20 |
DisclosureSEC source: 0001225208-24-005800 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 19, 2023. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 20:20 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-24-000026 · wk-form4_1711484443.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,754.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:45 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 1,465 | $76.21 | $111,647.65 |
DisclosureSEC source: 0001127602-24-009476 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,572 F3 · shares: Transaction pursuant to an existing Rule 10b5-1 trading plan adopted May 24, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:45 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,536 | $0.00 Strike: $76.32 | $0.00 |
DisclosureSEC source: 0001127602-24-009476 · form4.xml · derivative · entry 4 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,536 Underlying: Common Stock · 4,536 shares Expires 2034-03-07 F4 · derivative.exercise_date: Options become exercisable on the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:45 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009476 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,037 F1 · shares: Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,551 | $0.00 Strike: $38.44 | $0.00 |
DisclosureSEC source: 0001127602-24-000817 · form4.xml · derivative · entry 4 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,551 shares Expires 2028-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | HOLOGIC INC HOLX · Entity 12463 | SaleCommon Stock | 16,017 | $72.00 | $1,153,224.00 |
DisclosureSEC source: 0001127602-24-000817 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,465 F1 · shares: Transaction pursuant to an existing Rule 10b5-1 trading plan adopted May 24, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 7,551 | $38.44 | $290,260.44 |
DisclosureSEC source: 0001127602-24-000817 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction pursuant to an existing Rule 10b5-1 trading plan adopted May 24, 2023. F2 · balance_after: 3,206 shares of common stock were transferred from the Carol J. Dockendorff Revocable Trust to the direct ownership of the Reporting Person. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:23 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 10,215 | $87.68 | $895,651.20 |
DisclosureSEC source: 0001127602-23-023851 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,226 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated May 26, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.19 to $88.01, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 18, 2023 Filed Aug 18, 2023 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 17,079 | $50.74 | $866,631.16 |
DisclosureSEC source: 0001225208-23-008340 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,946 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 19, 2023. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $50.455 to $50.95, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:41 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022207 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,441 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 3,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005466 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,025 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:16 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-23-000035 · wf-form4_167942974534101.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,122.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 20:12 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,210 | $0.00 Strike: $78.49 | $0.00 |
DisclosureSEC source: 0001127602-23-009866 · form4.xml · derivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,210 Underlying: Common Stock · 4,210 shares Expires 2033-03-09 F3 · derivative.exercise_date: Options become exercisable on the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 20:12 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009866 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 F1 · shares: Represents restricted stock units which vest on the date of the 2024 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:13 UTC | HOLOGIC INC HOLX · Entity 12463 | GiftCommon Stock | 1,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004222 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GRAT Disclosed balance after: 0 F1 · ownership.nature: Represents a bona fide gift of shares of common stock from a grantor retained annuity trust to certain trusts for which the Reporting Person's children are beneficiaries. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:24 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GiftCommon Stock | 2,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-23-000002 · wf-form4_167338587484411.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 F1 · ownership.nature: On December 28, 2020, the reporting person contributed 10,209 shares of Keysight Technologies, Inc. common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Upon termination of the trust on January 6, 2023, 2,844 of the shares were transferred to the reporting person's children. The remaining 7,365 shares were returned to the reporting person and continue to be reported in this Form 4 as directly owned. Read SEC document |
| January 06, 2023 Filed May 5, 2023 20:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 8,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005466 · doc4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By GRAT 1 Disclosed balance after: 0 Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:08 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | SaleCommon Stock | 3,257 | $185.06 | $602,753.12 |
DisclosureSEC source: 0001601046-22-000158 · wf-form4_167105206970477.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,423.418 F1 · price: Average weighted price is $185.0639, with a range from $184.96 to $185.07. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:08 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GiftCommon Stock | 7,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-22-000158 · wf-form4_167105206970477.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,680.418 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020699 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,130 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 05, 2022 Filed May 9, 2022 20:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006716 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,079 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 20:15 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-22-000030 · wf-form4_164798012736526.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,231.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,293 | $0.00 Strike: $70.28 | $0.00 |
DisclosureSEC source: 0001127602-22-009139 · form4.xml · derivative · entry 4 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,293 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F5 · derivative.exercise_date: Options become exercisable on the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009139 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 F1 · shares: Represents restricted stock units which vest on the date of the 2023 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:22 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023395 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: Includes 8,568 shares previously held by a grantor retained annuity trust, of which Mr. Dockendorff is the sole trustee, pursuant to an exempt transfer by such trust. Read SEC document |
| May 06, 2021 Filed May 10, 2021 20:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 2,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007876 · doc4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,501 F2 · shares: Restricted stock granted in lieu of 75% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $105,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 06, 2021 Filed May 10, 2021 20:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007876 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,062 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2021 Filed Dec 7, 2021 21:16 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GiftCommon Stock | 3,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-21-000173 · wf-form5_163891177260113.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 F1 · ownership.nature: On February 28, 2019, the reporting person contributed 13,210 shares of Keysight Technologies, Inc. common stock to a grantor retained annuity trust for the benefit of himself and his two adult children. Upon termination of the trust on March 31, 2021, 3,240 of the shares were transferred to the reporting person's children. The remaining 9,970 shares were previously distributed to the reporting person and continue to be reported in this Form 5 as directly owned. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:30 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-21-000026 · wf-form4_161653142241583.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,845.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 22:28 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,055 | $0.00 Strike: $71.03 | $0.00 |
DisclosureSEC source: 0001127602-21-010635 · form4.xml · derivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,055 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F4 · derivative.exercise_date: Option becomes exercisable on the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 22:28 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010635 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,695 F1 · shares: Represents restricted stock units which vest on the date of the 2022 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.